Form 4: Immunome Inc. Chief Medical Officer Acquires 15,805 Shares

Immunome Inc.'s Chief Medical Officer, Robert Lechleider, purchased 15,805 shares of common stock at a price of $9.478 per share.

Summary

• Robert Lechleider, the Chief Medical Officer of Immunome Inc., acquired 15,805 shares of the company's common stock on November 21, 2024.
• The purchase was made at a price of $9.478 per share.
• The transaction was a direct purchase, increasing Mr. Lechleider's direct holdings of Immunome stock by 15,805 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive as an insider purchase can be seen as a sign of confidence, but it's a routine transaction.

Positives

• The purchase by a key executive may signal confidence in the company's future prospects.
• The transaction increases the executive's direct stake in the company.

Industry Context

This is a routine disclosure of an insider transaction, which is common in publicly traded companies. It does not indicate any specific industry trend.

Comparison to Industry Standards

• Insider transactions are a normal part of the operations of publicly listed companies.
• The size of the transaction is not unusual for an executive purchase of shares.
• Similar transactions are regularly reported by executives at comparable biotech companies.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the insider purchase.

Key Dates

Keywords

Immunome, IMNM, Robert Lechleider, Chief Medical Officer, stock purchase, insider trading, SEC Form 4